"I could go for a new contest; What is the RRR going to be?"

The overall %RRR for the time to first occurence of 3-point MACE for the total BETonMACE population is the primary endpoint. However, keep in mind that in addition to the %RRR for the total population are the pre-specified subgroup analyses for the primary endpoint in BETonMACE. Below are pre-specified analyses previously disclosed in slide decks from prior Corporate Updates or conference symposia. So assuming these are all part of the official pre-specified data analysis plan, things could get really interesting. The %RRR for the total population could only be scratching the surface.

– Rosuvastatin/Atorvastatin. When broken down by statin type, apabetalone may elicit a much greater %RRR in combo with rosuvastatin compared to atorvastatin.

– < 30 days/> 30 days post-acute coronary syndrome. Patients with a more recent ACS event (within 30 days or less prior to randomization) may experience a greater %RRR than in those patients with less recent ACS event (>30 days prior to randomization).

– LDL/HDL/TG’s above and below median. I'm not sure about LDL and TG, but patients with very low HDL (below median HDL levels) may experience a greater %RRR than in those patients with HDL levels above the median.

– HbA1c above and below median. Patients with more severe diabetes (HbA1c above the median ) may experience a greater %RRR than in those with less severe or better managed diabetes (HbA1c below the median). 

– eGFR >60 mL/min and < 60 mL/min. Patients with low baseline eGFR <60 mL/min may experience a greater %RRR than in those with a higher baseline eGFR >60 mL/min.

BearDownAZ